StockData
Bone Biologics Corp logo

Bone Biologics Corp (BBLG) company profile

BBLGNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 6/30
$0.29−0.02 (-5.92%)

Close on Nov 18, 2026Market cap $986.22KP/E –Yield –

About Bone Biologics

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration in spinal fusion surgery. Its core technology platform utilizes NELL-1, a proprietary recombinant human protein growth factor designed to regulate skeletal tissue formation and stem cell differentiation. The company's lead product candidate is NB1, a combination medical device that incorporates the NELL-1 recombinant protein with demineralized bone matrix (DBM). The product is designed to promote targeted bone growth during spinal fusion procedures, initially targeting adult patients with degenerative disc disease undergoing transforaminal lumbar interbody fusion. Beyond spinal applications, the company holds rights to develop the platform for osteoporosis and trauma treatments.

The company operates primarily through research, development, and clinical evaluation programs. Its pilot clinical study for the NB1 bone graft device is conducted across multiple centers in Australia, following preclinical testing in sheep models. Bone Biologics Corporation maintains its principal executive offices in Burlington, Massachusetts.

Summary of the business section of Bone Biologics's latest annual report, written by StockData.

Company profile

Company

Legal name
Bone Biologics Corp
Founded
2004
Headquarters
Burlington, MA
Address
2 Burlington Woods Drive,, Suite 100, 01803
Phone
(781) 552-4452
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Weinberg & Company, P.A, Los Angeles, California

Stock & identifiers

Ticker
BBLG
Exchange
Nasdaq
IPO date
Oct 13, 2021
Shares outstanding
3M, Oct 26, 2026
Public float
$7.23M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-6 reverse, Jun 10, 2025; 1-for-8 reverse, Dec 20, 2023; 1-for-30 reverse, Jun 7, 2023; 1-for-2.5 reverse, Nov 15, 2021; 1-for-10 reverse, Aug 14, 2018
SEC CIK
1419554
CUSIP
098070600
ISIN
US0980706008
FIGI
BBG007GF2K51
Share class FIGI
BBG007GF2K79
EIN
42-1743430

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jeff FrelickChief Executive Officer360
Deina H. WalshChief Financial Officer313
Robert E. GagnonDirector0
Phillip Terry Meikle IIDirector–
Bruce StroeverDirector0
Siddhesh Rajendra AngleDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$426.27K$430.79K$263.14K$0–
FY2024
Non Peo Neo
$242.45K$252.86K$242.45K$0–
FY2024
Peo
$384.90K$405.71K$242.45K$0–
FY2023$376.60K$332.97K$238.30K$0–
FY2022$414.72K$406.75K$250.46K$4–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
Jeffrey Frelick
Chief Executive Officer and President
$300.00K$26.27K$100.00K$426.27K+11%
Deina Walsh
Chief Financial Officer
$200.00K$13.14K$50.00K$263.14K+9%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Corporate history

Events identified from SEC filings

See a number that looks wrong?